|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the molecular level, MTDH has been shown to interact with proteins that drive tumorigenesis, including nuclear factor-κB (NF-κB), promyelocytic leukaemia zinc finger (PLZF), BRCA2- and CDKN1A (p21Cip1/Waf-1/mda-6)-interacting protein α (BCCIPα) and staphylococcal nuclease and tudor domain containing 1 (SND1).
|
28627585 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We followed 7243 women with a BRCA1 or a BRCA2 mutation for incident cases of leukaemia.
|
26986251 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, bi-allelic mutations in BRCA2 are linked to FA, a rare chromosome instability syndrome characterized by aplastic anemia in children as well as susceptibility to leukemia and cancer.
|
27530658 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Children with biallelic mutations in FANCD1/BRCA2 are at uniquely high risks of leukemia and solid tumors.
|
26183081 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a minority of cases, FA results from biallelic FANCD1/BRCA2 mutations that are associated with early-onset leukaemia and solid tumours.
|
24301060 |
2014 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BRCA-deficient status predisposing to RAD52-dependent synthetic lethality could be predicted by genetic abnormalities such as oncogenes BCR-ABL1 and PML-RAR, mutations in BRCA1 and/or BRCA2 genes, and gene expression profiles identifying leukemias displaying low levels of BRCA1 and/or BRCA2.
|
23836560 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Biallelic FANCD1/BRCA2 mutations are the genetic basis of disease in a small proportion of children with FA with earlier onset and increased incidence of leukemia and solid tumors.
|
21548014 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The small group of patients with biallelic mutations in BRCA2 is distinctive in the severity of the phenotype, and early onset and high rates of leukaemia and specific solid tumours, and may comprise an extreme variant of Fanconi anaemia.
|
16825431 |
2007 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was designed to test the hypothesis that inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias.
|
17683622 |
2007 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that BRCA2 testing should be considered in all patients with FA in whom the complementation group cannot be defined or in whom leukemia is diagnosed at or before 5 years of age.
|
15070707 |
2004 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Our results suggest that BRCA2 testing should be considered in all patients with FA in whom the complementation group cannot be defined or in whom leukemia is diagnosed at or before 5 years of age.
|
15070707 |
2004 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tumours of the stomach and cervix, as well as melanoma and leukaemia/lymphoma also occur in these pedigrees but the numbers are too low to determine whether they may be significantly associated with BRCA2 carrier status.
|
8682513 |
1996 |